Collegium Pharmaceutical
COLL
Constellation Brands
STZ
Ermenegildo Zegna NV
ZGN
DexCom
DXCM
Workday
WDAY
US Stock MarketDetailed Quotes
ALLK Allakos
- 1.210
- +0.180+17.48%
Close Jan 24 16:00 ET
- 1.220
- +0.010+0.83%
Post 20:01 ET
108.11MMarket Cap-0.60P/E (TTM)
1.260High1.040Low1.18MVolume1.070Open1.030Pre Close1.40MTurnover1.99%Turnover RatioLossP/E (Static)89.34MShares1.69052wk High1.49P/B72.19MFloat Cap0.53552wk Low--Dividend TTM59.66MShs Float157.980Historical High--Div YieldTTM21.36%Amplitude0.535Historical Low1.184Avg Price1Lot Size
Allakos News
JMP Securities Initiates Allakos(ALLK.US) With Buy Rating, Announces Target Price $3
JMP Securities Maintains Allakos(ALLK.US) With Buy Rating, Maintains Target Price $3
Promising Potential of Allakos's AK006 Drives Buy Rating Amidst Market Interest in Chronic Spontaneous Urticaria
Allakos Reports Q3 2024 Results and Research Progress
Allakos Inc. Alters Lease Agreement for Cost Savings
All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy
A Quick Look at Today's Ratings for Allakos(ALLK.US), With a Forecast Between $1 to $7
Cautious Hold Rating for Allakos Amid Uncertain Clinical and Financial Outlook
Piper Sandler Maintains Allakos(ALLK.US) With Buy Rating, Maintains Target Price $7
Barclays Maintains Allakos(ALLK.US) With Sell Rating, Maintains Target Price $1
Allakos GAAP EPS of -$0.21 Beats by $0.03
Allakos (ALLK) Gets a Hold From TD Cowen
Express News | Allakos Inc Q3 Shr View $-0.25 -- LSEG IBES Data
Express News | Allakos Inc: Reiterates That It Expects Restructuring Activities Will Extend Cash Runway Into Mid-2026
Allakos | 10-Q: Q3 2024 Earnings Report
Allakos | 8-K: Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
Allakos 3Q Loss/Shr 21c >ALLK
Press Release: Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
Express News | Allakos Q3 Net Income USD -18.372 Million
Express News | Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results